The firm is selling BioServe to Reprocell as part of Cancer Genetics' transformation and strategic plan to bring itself to profitability.
DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.
The firm plans to use $110 million of the net cash proceeds to pay down debt.
Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
The sale of assets to the Institute for Environmental Health comes after an extensive review of strategic alternatives for Roka, the company said.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
After selling Focus Diagnostics' products business to DiaSorin for $300 million, Quest now estimates annual revenues of between $7.47 billion and $7.54 billion.
The company said selling this business unit frees it to focus on developing new maternal and fetal health solutions for the US and elsewhere.
Hologic will purchase the assets via its subsidiary Gen-Probe, from which DiagnoCure will repurchase Series A shares worth C$1 million.
Tute will offer interpretation and annotation software from Knome's KnoSys appliance as part of its existing cloud offering but is open to providing a local option for interested clients.
Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.
In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.